Schema-Root.org logo

 

  cross-referenced news and research resources about

 province of Galapagos, Ecuador

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Wed. March 30, 2022

-
Landscape Capital Management L.L.C. boosted its holdings in shares of Galapagos NV (NASDAQ:GLPG) by 27.5% during the 4th quarter, according to the ... and six have assigned a buy rating to the company. Galapagos currently has a consensus rating of “Hold” and an average target price of $111.00.
Finally, Zacks Investment Research upgraded Galapagos from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. Galapagos ...

Finally, BidaskClub downgraded Galapagos from a sell rating to a strong sell rating in a research report on Saturday, December 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. Galapagos has an average ...
Finally, ValuEngine downgraded Galapagos from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Galapagos presently has a ...
Galapagos NV logo ValuEngine upgraded shares of Galapagos (NASDAQ:GLPG) from a sell rating to a hold rating in a report issued on Friday, February ... a hold rating and seven have assigned a buy rating to the company. Galapagos has an average rating of Buy and an average target price of $111.00.
... Stifel Nicolaus reaffirmed a buy rating and set a $120.00 price target on shares of Galapagos in a research report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Galapagos ...

Finally, ValuEngine cut Galapagos from a hold rating to a sell rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Galapagos has a consensus rating of Buy and ...
Finally, BidaskClub cut Galapagos from a sell rating to a strong sell rating in a research note on Saturday, December 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Galapagos has an average ...
Gilead made a $425 million investment in Galapagos shares, which bought them 6,760,701 shares of Galapagos, 13.27% of the total number of outstanding shares. In addition to that, Gilead paid a $300M license payment and further payments up to $1.35B can come from royalties and profit sharing.
Biotech company Galapagos has opted to co-promote filgotinib with its partner Gilead Sciences should the drug be approved in Europe, according to a press release. Filgotinib is an investigational oral Janus kinase 1 (JAK1)-selective inhibitor under evaluation in Crohn's disease, ulcerative colitis and ...
In a previous note to my subscribers, I said that Galapagos NV (NASDAQ:GLPG) is a strong buy after Celgene's dramatic failure in Crohn's Disease or CD, because its lead candidate filgotinib is now the most advanced drug in anybody's CD pipeline. The Celgene (NASDAQ:CELG) drug was thought to ...
Vertex Pharmaceuticals Incorporated VRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. Vertex reported revenues of ...
The stock price of NASDAQ-listed Belgian company Galapagos NV ADR (GLPG) started soaring mid-September onwards amid rumors of the company being a possible takeover target by Gilead Sciences Inc. (GILD). Following a 10-day long rally which resulted in a 35% spike in share price, the price is ...
Finally, Zacks Investment Research downgraded Galapagos from a hold rating to a sell rating in a research report on Wednesday, December 27th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Galapagos currently has an ...
... target on shares of Galapagos in a research note on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Galapagos has an average rating of Buy and an average price target of $111.00.
Finally, ValuEngine lowered Galapagos from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. Galapagos presently has a consensus ...
... target on shares of Galapagos in a research note on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Galapagos has an average rating of Buy and an average price target of $111.00.

Galapagos NV logo ValuEngine upgraded shares of Galapagos (NASDAQ:GLPG) from a sell rating to a hold rating in a report published on Friday, ... given a hold rating and seven have assigned a buy rating to the company. Galapagos has an average rating of Buy and a consensus target price of $111.00.
... on shares of Galapagos in a research note on Sunday, October 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Galapagos currently has an average rating of “Buy” and an average price target of $111.00.
... $92.00) on shares of Galapagos in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. Galapagos currently has a consensus rating of Buy and an average target price of $111.00.
Finally, ValuEngine lowered shares of Galapagos from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Galapagos presently has a consensus rating of ...
Finally, ValuEngine downgraded Galapagos from a hold rating to a sell rating in a report on Friday, December 1st. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Galapagos currently has an average rating of ...
Finally, Nomura boosted their price target on Galapagos from $108.00 to $124.00 and gave the company a “buy” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. Galapagos ...
Biotech company Galapagos has opted to co-promote filgotinib with its partner Gilead Sciences should the drug be approved in Europe, according to a press release. Filgotinib is an investigational oral Janus kinase 1 (JAK1)-selective inhibitor under evaluation in Crohn's disease, ulcerative colitis and ...
Galapagos (NASDAQ:GLPG) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on ... hold rating and six have given a buy rating to the company. Galapagos currently has an average rating of “Hold” and a consensus price target of $111.00.
... shares of Galapagos in a report on Thursday, September 14th. They set a “sector perform” rating and a $98.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. Galapagos has ...
As with most recent Gilead articles, the one from Meyers also discusses the reason why GILD shares continue to underperform. Since mid-2015, Gilead has struggled due to a range of factors. The stock was initially impacted by the general sell-off in the biotech industry. The first of these happened in the ...
In a previous note to my subscribers, I said that Galapagos NV (NASDAQ:GLPG) is a strong buy after Celgene's dramatic failure in Crohn's Disease or CD, because its lead candidate filgotinib is now the most advanced drug in anybody's CD pipeline. The Celgene (NASDAQ:CELG) drug was thought to ...
Vertex Pharmaceuticals Incorporated VRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. Vertex reported revenues of ...
Vertex Pharmaceuticals Incorporated VRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. Vertex reported revenues of ...
Belgian clinical-stage biotech company Galapagos (Euronext: GLPG) is currently working on an agent called GLPG1690, an inhibitor of autotaxin for use in patients with a lung disorder named idiopathic pulmonary fibrosis. This continues to be an area of unmet need, as only two drugs are currently ...
Researchers conducting a Phase 1 study for cystic fibrosis (CF) have dosed their first healthy volunteer with a combination of the novel drugs GLPG2222 (a corrector) and GLPG2451 (a potentiator), the Belgian company Galapagos announced. The randomized, placebo-controlled study (NCT02788721) ...
One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. Galapagos currently has a consensus rating of “Buy” and a consensus target price of $111.00. Shares of Galapagos (GLPG) traded up $1.51 during ...
Finally, ValuEngine cut Galapagos from a hold rating to a sell rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Galapagos has a consensus rating of Buy and ...
Finally, BidaskClub cut Galapagos from a sell rating to a strong sell rating in a research note on Saturday, December 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Galapagos has an average ...
Galapagos NV (NASDAQ:GLPG) – Stock analysts at Jefferies Group cut their FY2017 EPS estimates for shares of Galapagos in a report released on ... and seven have assigned a buy rating to the company. Galapagos presently has an average rating of “Hold” and a consensus target price of $111.00.
Finally, ValuEngine lowered shares of Galapagos from a hold rating to a sell rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Galapagos currently has a ...
... on shares of Galapagos in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. Galapagos presently has an average rating of “Hold” and a consensus price target of $111.00.
Finally, Nomura began coverage on shares of Galapagos NV in a report on Wednesday, March 1st. They issued a buy rating for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Galapagos NV has an average ...
Finally, BidaskClub upgraded Galapagos from a sell rating to a hold rating in a research note on Thursday, August 17th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Galapagos currently has a consensus rating of Buy and an average price ...
In a previous note to my subscribers, I said that Galapagos NV (NASDAQ:GLPG) is a strong buy after Celgene's dramatic failure in Crohn's Disease or CD, because its lead candidate filgotinib is now the most advanced drug in anybody's CD pipeline. The Celgene (NASDAQ:CELG) drug was thought to ...
Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Galapagos NV presently has an average rating of “Buy” and an average price target of $108.14. Galapagos NV (GLPG) traded up 1.20% during midday trading on Friday, reaching $97.17.
Vertex Pharmaceuticals Incorporated VRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. Vertex reported revenues of ...
Belgian clinical-stage biotech company Galapagos (Euronext: GLPG) is currently working on an agent called GLPG1690, an inhibitor of autotaxin for use in patients with a lung disorder named idiopathic pulmonary fibrosis. This continues to be an area of unmet need, as only two drugs are currently ...
Researchers conducting a Phase 1 study for cystic fibrosis (CF) have dosed their first healthy volunteer with a combination of the novel drugs GLPG2222 (a corrector) and GLPG2451 (a potentiator), the Belgian company Galapagos announced. The randomized, placebo-controlled study (NCT02788721) ...
The stock price of NASDAQ-listed Belgian company Galapagos NV ADR (GLPG) started soaring mid-September onwards amid rumors of the company being a possible takeover target by Gilead Sciences Inc. (GILD). Following a 10-day long rally which resulted in a 35% spike in share price, the price is ...
Stifel Nicolaus increased their target price on shares of Galapagos NV ... a buy rating to the company. Galapagos NV presently has an average ...
Galapagos NV (NASDAQ:GLPG) was upgraded by stock analysts at ... a buy rating to the company. Galapagos NV presently has an average ...
Belgian clinical-stage biotech company Galapagos (Euronext: GLPG) is currently working on an agent called GLPG1690, an inhibitor of ...
BidaskClub cut shares of Galapagos NV (NASDAQ:GLPG) from a hold ... rating to the company. Galapagos NV has an average rating of Buy ...


 

news and opinion


 


 


 


 


schema-root.org

    ecuador
     provinces
       galapagos

Ecuador provinces:
       azuay
       bolivar
       canar
       carchi
       chimborazo
       cotopaxi
       el oro
       esmeraldas
       galapagos
       guayas
       imbabura
       loja
       los rios
       manabi
       morona‑santiago
       napo
       orellana
       pastaza
       pichincha
       sucumbios
       tungurahua
       zamora‑chinchipe

cross-references for
galapagos:

Galapagos